<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40177">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01893723</url>
  </required_header>
  <id_info>
    <org_study_id>2011-A00947-34</org_study_id>
    <nct_id>NCT01893723</nct_id>
  </id_info>
  <brief_title>Analgesia Nociception Index Guided Remifentanil Administration During Propofol Anesthesia for Laparoscopic Surgery</brief_title>
  <official_title>Analgesia Nociception Index Guided Remifentanil Administration During Propofol Anesthesia for Laparoscopic Surgery : Multicenter Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Physiodoloris (MetroDoloris, Lille, France) monitor, CE marqued, uses the ECG signal in
      order to compute the Analgesia Nociception Index (ANI) which has been shown to measure the
      relative parasympathetic tone, and hence to reflect the analgesia/nociception balance during
      general anesthesia. The primary endpoint of this randomized multicenter study is to measure
      whether there is a benefit to use the ANI in order to adapt remifentanil administration
      during propofol anesthesia for laparoscopic surgery. Primary endpoint : lesser proportion of
      patients presenting with at least one episode of hemodynamic reactivity, hypotension or
      bradycardia in the ANI guided group vs control group ?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Physiodoloris (MetroDoloris, Lille, France) monitor, CE marqued, uses the ECG signal in
      order to compute the Analgesia Nociception Index (ANI) which has been shown to measure the
      relative parasympathetic tone, and hence to reflect the analgesia/nociception balance during
      general anesthesia. The primary endpoint of this randomized multicenter study is to measure
      whether there is a benefit to use the ANI in order to adapt remifentanil administration
      during propofol anesthesia for laparoscopic surgery. Primary endpoint is: lesser proportion
      of patients presenting with at least one episode of hemodynamic reactivity, hypotension or
      bradycardia in the ANI guided group vs control group ?
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Proportion of patients presenting at least once with hemodynamic reactivity, hypotension or bradycardia</measure>
    <time_frame>end of surgery (around 60 to 90 min after start)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>total administered remifentanil</measure>
    <time_frame>end of surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of target changes</measure>
    <time_frame>end of surgery (around 60 to 90 min after start)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>morphine sulfate total administration after end of surgery</measure>
    <time_frame>during two hours after end of surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale evaluation of pain after surgery</measure>
    <time_frame>during two hours after end of surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ANI measure during surgery</measure>
    <time_frame>from start to end of surgery (around 60 to 90 min)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of bradycardia and hypotension</measure>
    <time_frame>from start to end of surgery (around  60 to 90 min )</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total administered dose of ephedrine</measure>
    <time_frame>between start and end of anesthesia</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">164</enrollment>
  <condition>General Anesthesia</condition>
  <arm_group>
    <arm_group_label>ANI guided remifentanil arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>remifentanil targets are increased or decreased depending on ANI readings. In case of high blood pressure associated with elevated ANI, nicardipine is administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ANI blind arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>remifentanil target is adapted as is usual during general anesthesia, depending on hemodynamic reactions to nociceptive surgical stimulations. In case of elevated blood pressure despite a maximum target of 10 ng/ml (Minto Pk/pD model), then nicardipine is administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ANI guided remifentanil</intervention_name>
    <description>remifentanil administration during propofol anesthesia for laparoscopic surgery is  ANI guided</description>
    <arm_group_label>ANI guided remifentanil arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ANI blind arm</intervention_name>
    <description>remifentanil administration during propofol anesthesia for laparoscopic surgery is not ANI guided</description>
    <arm_group_label>ANI blind arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  laparoscopic cholecystectomy or gynecological laparoscopic surgery

          -  ASA I or II

          -  adult patient

          -  body mass index between 17 and 33 kg/m2

        Exclusion Criteria:

          -  pregnancy

          -  arrhythmia

          -  pace maker

          -  diabetes mellitus

          -  dysautonomia

          -  treatment with beta blocking agents
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mathieu JEANNE, MD</last_name>
    <phone>+33 3 20 44 40 74</phone>
    <email>mathieu.jeanne@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Erasme (ULB)</name>
      <address>
        <city>Brussel</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luc BARVAIS, Prof</last_name>
      <email>luc.barvais@erasme.ulb.ac.be</email>
    </contact>
    <investigator>
      <last_name>Luc BARVAIS, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles LEBUFFE, Pr</last_name>
      <phone>+33 3 20 44 45 08</phone>
      <email>gilles.lebuffe@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Gilles LEBUFFE, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Roger Salengro</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathieu JEANNE, MD</last_name>
      <phone>+33 3 20 44 40 74</phone>
      <email>mathieu.jeanne@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Mathieu JEANNE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Saint Etienne</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Serge MOLLIEX, Pr</last_name>
      <phone>+33 4 77 12 03 88</phone>
      <email>serge.molliex@chu-st-etienne.fr</email>
    </contact>
    <investigator>
      <last_name>Serge MOLLIEX, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 2, 2013</lastchanged_date>
  <firstreceived_date>June 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>autonomous nervous system monitoring</keyword>
  <keyword>analgesia nociception balance</keyword>
  <keyword>remifentanil</keyword>
  <keyword>analgesia nociception index</keyword>
  <keyword>hemodynamic reactivity</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
